게피티닙 치료로 호전된 폐선암의 전이성 수막암종증 1예
A case of leptomeningeal metastasis from adenocarcinoma of the lung improved by treatment with Gefitinib
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Leptomeningeal metastasis occurs in approximately 1% of patients with non-small cell lung cancer and this is an extremely serious complication. Without treatment, the median survival of patients is 4~6 weeks. The treatment options currently available are limited and achieve only modest results. Gefitinib was recently approved for the treatment of advanced/refractory non-small cell lung cancer. In addition, there have been case reports showing activity of gefitinib against brain metastasis in non-small cell lung cancer patients. However, there is limited data on the ability of gefitinib to cross the blood-brain barrier. We report the case of a patient with leptomeningeal metastasis from adenocarcinoma of the lung that had a dramatic response to gefitinib treatment. (Korean J Med 74:198-202, 2008)
Abstract
Leptomeningeal metastasis occurs in approximately 1% of patients with non-small cell lung cancer and this is an extremely serious complication. Without treatment, the median survival of patients is 4~6 weeks. The treatment options currently available are limited and achieve only modest results. Gefitinib was recently approved for the treatment of advanced/refractory non-small cell lung cancer. In addition, there have been case reports showing activity of gefitinib against brain metastasis in non-small cell lung cancer patients. However, there is limited data on the ability of gefitinib to cross the blood-brain barrier. We report the case of a patient with leptomeningeal metastasis from adenocarcinoma of the lung that had a dramatic response to gefitinib treatment. (Korean J Med 74:198-202, 2008)
참고문헌 (12)
- Larson DA, "Carcinomatous meningitis, in : Cancer, pirnciples and practice of oncology. 7th ed", pp.2333~2335 (2005), Williams & Wilkins
- Gleissner B, "Neoplastic meningitis", Lancet Neurol, 5, pp.443~452 (2006)
- Glass JP, "Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology", Neurology, 29, pp.1369~1375 (1979)
- Grossman SA, "Leptomeningeal carcinomatosis", Cancer Treat Rev, 25, pp.103~119 (1999)
- Brehmer D, "Cellular targets of gefitinib", Cancer Res, 65, pp.379~382 (2005)
- Cappuzzo F, "Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)", Lung Cancer, 41, pp.227~231 (2003)
- Chiu CH, "Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity", Lung Cancer, 47, pp.129~138 (2005)
- Sakai M, "Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib", Int J Clin Oncol, 11, pp.243~245 (2006)
- Wasserstrom WR, "Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients", Cancer, 49, pp.759~772 (1982)
- Yoshida S, "Intrathecal chemotherapy for patients with meningeal carcinomatosis", Surg Neurol, 36, pp.52~55 (2005)
- Grant R, "Clinical outcome in aggressively treated meningeal carcinomatosis", Arch Neurol, 51, pp.457~461 (1994)
- Shah NT, "Practical management of patients with non-small-cell lung cancer treated with gefitinib", J Clin Oncol, 23, pp.165~174 (2005)